TransMedics Group, Inc.

TransMedics Group, Inc.

TMDX·NASDAQ

$69.69

+3.2%
HealthcareMedical - Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

At a Glance

Live Snapshot
Market Cap$2.41B
EPS5.6000
P/E Ratio12.44
Earnings Date07/29/2026

tmdx

Cash at Beginning of Period

Last Annual Value

337.15M

3-Year CAGR

135%

5-Year CAGR

75%

10-Year CAGR

41%

TransMedics Group, Inc.

TransMedics Group, Inc. Competitors Analysis of Cash at Beginning of Period

TMDX · NASDAQ
CompanyCash at Beginning of Period
CAGR 3Y
CAGR 5Y
CAGR 10Y
337.15M
18.7%68.1%41.4% 
234.21M
-2.1%4.6%N/A
174.36M
13.4%12.5%23.2%
186.70M
-34.0%-22.9%-3.5%
302.59M
-0.0%N/AN/A
126.05M
19.1%31.1%N/A
319.00M
-25.6%-18.0%-4.1%
771.74M
18.2%140.2%N/A
1.55B
-0.6%13.0%N/A
412.56M
11.9%33.0%38.8%
IMVT logo
Immunovant, Inc.
NASDAQ:IMVT
713.97M
13.1%48.0%N/A
TransMedics Group, Inc.

TransMedics Group, Inc. Fair Value Envelope

TMDX · NASDAQ

Our analysis suggests that TMDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $69.69, this represents a potential HIDDEN relative to our calculated worth for TransMedics Group, Inc..

Intrinsic Value
Current Price: $69.69